Edgestream Partners L.P. Sells 19,845 Shares of Merck & Co., Inc. $MRK

by · The Markets Daily

Edgestream Partners L.P. lowered its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 86.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,181 shares of the company’s stock after selling 19,845 shares during the period. Edgestream Partners L.P.’s holdings in Merck & Co., Inc. were worth $383,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC increased its stake in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the period. Diversify Advisory Services LLC lifted its stake in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after acquiring an additional 359,356 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

  • Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue grew 5.1% year over year. Merck posts better-than-expected second-quarter results on Keytruda strength
  • Positive Sentiment: Keytruda remained the primary growth driver, generating $8.37 billion in quarterly sales, while the injectable formulation substantially exceeded Wall Street expectations. Newer products and pipeline programs also supported the company’s performance. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
  • Positive Sentiment: Merck raised its 2026 revenue outlook to $66.3 billion-$67.3 billion, reflecting confidence in Keytruda, newer launches and pipeline progress. Guggenheim also raised its price target to $146 and maintained a Buy rating. MRK Q2 Earnings & Sales Beat Estimates, ’26 Sales View Raised
  • Positive Sentiment: Health Canada approved Keytruda combined with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s commercial reach. Health Canada approves Keytruda treatment
  • Neutral Sentiment: Merck is accelerating acquisitions and partnerships in hematology, infectious diseases, vaccines, cardiopulmonary medicine and obesity to diversify ahead of Keytruda’s expected U.S. patent-exclusivity loss in 2028. The strategy offers long-term upside but increases execution and spending risks. Merck is racing beyond Keytruda
  • Negative Sentiment: Merck lowered its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus, primarily because of acquisition-related charges tied to Terns Pharmaceuticals and other deals. Merck hikes revenue outlook but cuts profit guidance
  • Negative Sentiment: Investors remain concerned that Keytruda’s 2028 patent cliff could create a significant revenue gap unless newer products, acquisitions and clinical programs deliver sufficient replacement growth. Merck also reported a mixed development update for anti-TL1A drug tulisokibart, which was discontinued in one rare lung-disease indication. MSD posts a victory and defeat for anti-TL1A

Wall Street Analyst Weigh In

MRK has been the subject of several recent research reports. Barclays boosted their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. CICC Research started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. JPMorgan Chase & Co. boosted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Citigroup started coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective on the stock. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.56.

Check Out Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Trading Up 0.3%

NYSE:MRK opened at $128.33 on Thursday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05. The firm has a market capitalization of $316.95 billion, a price-to-earnings ratio of 102.66, a PEG ratio of 5.13 and a beta of 0.19. The business’s 50-day moving average price is $123.61 and its two-hundred day moving average price is $118.91.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 2.72 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).